https://www.selleckchem.com/pr....oducts/alantolactone
nt subset for dual AR/Akt inhibition may optimize precision treatment with Akt inhibitors in mCRPC.Germline likely pathogenic or pathogenic variants (PVs) have been identified in up to 17% of men with prostate cancer (PC) and may drive disease severity or be targetable by novel therapies. National Comprehensive Cancer Network (NCCN) guidelines encouraging germline testing in metastatic PC were recently expanded to include all men with high-risk, very high-risk, or regional PC. Our aim was to assess the impact of expanded NCCN guid
Like
Comment
Share
